Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

NCT04347239 is registered in ClinicalTrials.gov with CytoDyn, Inc. as lead sponsor.

NCT NCT04347239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04347239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Lead sponsor
CytoDyn, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 16, 2020
Completion date
June 15, 2022
Enrollment
484 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019